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from each patient's treatment plan were calculated. 
Spearman's rank correlation and multivariable regression 
analysis tested for association between the BEDs and the OS 
and PFS respectively. Of each BED, medians were used to 
split the distribution into two groups: above and below 
median for the Mann Whitney U test analysis.  
Results: Between September 2010 and March 2014, 33 
consecutive patients with unresectable nodal metastases 
were included in the study. The median of follow-up is 21.10 
months and the median of patient's age is 67.76 years old. 
Anatomical location of sites treated: Neck (n=2), Abdomen 
(n=19), and Pelvis (n=12). Histopathology of Primary: 
Colorectal (n=20), Breast (n=2), Urological (n=5), Gynae 
(n=2), and Other/Unknown primary (n=4). The medians and 
95% confidence intervals (CI) of OS, PFS, BED of prescription 
dose, GTVmin, GTVmean, PTVmin and PTVmean are 
summarised in table 1. 
 
 Median 95% CI 
OS (months) 19.03 15.39-22.74 
PFS (months) 12.27 10.88-17.64 
Prescription dose BED (Gy10) 51.30 52.48-60.72 
GTVmin BED (Gy10) 60.52 56.87-69.02 
GTVmean BED (Gy10) 78.41 74.76-90.39 
PTVmin BED (Gy10) 47.74 44.00-53.12 
PTVmean BED (Gy10) 69.57 67.62-79.65 
 
The results of the correlation analysis suggested that GTVmin 
(R=0.42, p<0.05) correlated to OS and PTVmin (R=0.48, 
p<0.05) correlated to PFS the most among all BEDs. Multiple 
linear regression analysis was used to develop a model for 
predicting OS and PFS from the dosimetric parameters. Both 
models for OS (F=2.04, df=5,27, p=0.11) and PFS (F=1.79, 
df=5,27 p=0.15) are not statistically significant. No significant 
differences were found in OS between the above and below 
median groups for all BEDs (p<0.05). Significant differences 
were found in PFS between the above and below median 
groups for all BEDs (p<0.05) apart from GTVmean BED 
(p=0.19).  
Conclusions: Our analysis of the data suggested that the 
level of dose received by tumours influenced PFS and this 
relationship was not found between the dosimetric 
parameters and OS. 
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Purpose/Objective: Many patients with advanced cancer 
develop bone metastases, with pain as a common and 
devastating consequence. Adequate treatment is important 
to maintain or improve quality of life (QoL). In 2002, an 
international consensus on palliative radiotherapy endpoints 
was established to improve comparability of trial results. 
Clinical trials using this consensus reported high response 
rates (60% using intention to treat (ITT) analysis, and up to 
80% in assessable patients only), indicating that palliative 
radiotherapy is an effective treatment. Clinical trials usually 
use strict inclusion criteria, resulting in selected patient 
groups and limited generalizability of results. The aim of this 
study is to estimate response to palliative radiotherapy in an 
unselected cohort of patients with bone metastases. 
Materials and Methods: Since June 2013, all patients with 
bone metastases requiring radiotherapy for pain or 
neurological complaints or for postoperative radiotherapy 
after fixation, who are treated at our department, are 
prospectively included in an ongoing cohort. Pain items using 
the Brief Pain Inventory and QoL variables using the PAL 15 
and BM 22 are obtained at baseline, and in weeks 4, 6 and 8 
following radiotherapy. For each patient, the best response 
outcome is calculated according to the international 
consensus criteria. Responders are patients with a complete 
or partial response, patients with pain increase, stable pain 
or undetermined response are regarded non-responders. 
Descriptive statistics were provided. Here we present the 
first outcome regarding pain outcome. 
Results: Until September 2014, 92% (n=238/258) of patients 
who were asked to participate were included. Patients 
requiring postoperative radiotherapy were excluded. Median 
age of the remaining 213 patients was 66 years (range 35-88). 
Median survival was 8 months (range 0-15 months). Most 
common primary cancer sites were prostate (31%), lung 
(25%), and breast (20%). 18 patients (9%) underwent 
radiotherapy because of neurological complaints. Median 
performance status as measured by KPS score was 70 (range 
20-100). Mean baseline pain scores at the irradiated sites was 
5.5 (SD + 2.6) with a median daily oral morphine equivalent 
dose intake of 74 mg (range 0-840 mg). Response rates of 176 
patients (83%) were available. 109 patients (62%) 
experienced a complete or partial response, whereas 67 
patients (38%) were classified as non-responders. However 
the ITT effect is lower: 51% of the patients experience pain 
relief (see table). 
 
 
Conclusions: The first response outcomes in this hospital 
based prospective cohort are lower than the response rates 
found in clinical trials. Continuous focus should be to predict 
which patients are most likely to respond, and which are not. 
We intend to proceed with the prospective data collection to 
be able to report on subgroup analyses, and QoL since 
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additional palliative measures remain essential for adequate 
pain control. 
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Purpose/Objective: Graves’ Ophthalmopathy is the 
commonest extrathryoidal manifestation of Graves’ disease. 
The underlying pathogenesis is believed to be autoimmune-
related leading to excessive infiltration of lymphocytes and 
excessive production of hydrophilic glycosaminoglycans and 
subsequently expansion of retro-orbital tissues and 
enlargement of extraocular muscles. Treatment options 
include steroid therapy, corrective/decompressive surgery, 
radiation therapy or combination of these approaches. Our 
purpose is to investigate if retro-orbital irradiation with 
Inverse VMAT IMRT planning produced better target coverage 
and dose sparing to adjacent normal structures as compared 
with Forward IMRT and 3D conformal for patients with 
bilateral Graves’ Ophthalmopathy. 
Materials and Methods: Fourteen consecutive patients 
diagnosed with bilateral Graves’ Ophthalmopathy were 
prospectively recruited into this study. An individual Inverse 
VMAT IMRT planning, Forward IMRT and 3D conformal plan 
was created for each patient. Conformity Index (CI), 
Homogeneity Index (HI) and other dosimetric parameters of 
the targets and organs-at-risk (OAR) were compared between 
the different techniques. Statistical analysis was T-student. 
Results: CI generated by Inverse VMAT IMRT planning was 
superior to that produced by Forward IMRT and 3D conformal 
(p<.001 for both respectively). As expected Forward IMRT 
was superior to 3D conformal (p=.007). However the 
differences in the HI was not significant.  Inverse VMAT IMRT 
planning resulted in better OARs dose sparing (globe, lens, 
retina, lacrimal gland, optic nerve) with the exception of the 
optic chiasm that received a higher dose. The differences in 
the dose sparing of the OARs didn’t shown a significant 
difference when comparing Forward IMRT to 3D conformal. 
 Conclusions: Inverse VMAT IMRT planning is superior to 
Forward IMRT and 3D conformal for bilateral Graves’ 
Ophthalmopathy treatment in virtue of the benefit on the 
target coverage, better CI with similar HI, and better sparing 
of the OARs, despite an increase in treatment planning and 
delivery time, consumption of monitor units and a slightly 
increased but clinically negligible dose to some surrounding 
structures. 
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Purpose/Objective: To identify predictive factors of local 
control (LC) and develop a model for estimating tumor 
response in patients with cranial and extracranial 
oligometastases treated by hypofractionated stereotactic 
radiotherapy (SBRT/SRS). 
Materials and Methods: Clinical data from 79 patients who 
received hypofractionated SBRT/SRS for cranial and 
extracranial oligometastases (£ 5 lesions), with different 
primary tumor, primary histology, and metastatic lesions 
(lung, liver, brain, adrenal gland) were collected. Maximum 
local response was evaluated according to RECIST criteria. 
Univariate and multivariate analysis were performed to 
identify best significant predictors for local control. A dose-
response model estimating the maximum tumor response to 
treatment has been defined. 
Results: Main histological type was adenocarcinoma (62%). 
The most frequent primary tumor was colorectal cancer 
(44%); main oligometastastic sites were lung (58%), brain 
(22%), liver (15%), and adrenal gland (5%). The Median 
prescribed BED10 was 71.8 Gy (range, 45-100.8). The overall 
response rate was 61%. Median LC was 27.9 months, with a 2 
years LC rate of 60%. Univariate analysis defined 2 patient-
inherent factors indipendently related to LC: primary 
colorectal cancer (negative predictor, p=0.01), and the dose 
normalized to pretreatment lesion volume (ND; see equation) 
(positive predictor, p=0.02).Significant variables for LC on 
univariate analysis were tested in multivariate analysis. A 
logistic linear generalized model was fitted to data (figure). 
The model performed well for the ND (p=0.004). The 
evaluation method shows the Poisson model as good 
compromise between prediction power (TD50=16.1, 
g50=0.53; AIC=97.43, AUC=0.7045) and model simplicity. 
 
 
Figure: plot of the three dose-response models fitted to data, 
Logit (blue), LogLogit (red), Poisson (green). Confidence 
intervals for TCP and ND (BED/logVol) have been calculated 
by using bootstrapping 5000 sample series based on the initial 
dataset. 
Conclusions: The proposed model performed well, it was 
internal successfully validated, and showed the ability to 
predict a dose-response relationship between the prescribed 
dose, the lesion volume and the maximum response to 
hypofractionated stereotactic radiotherapy for 
oligometastatic patients. Future researches should be 
directed to test the model on more numerous and prognostic 
variables-based series of patients. 
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Purpose/Objective: Modern systemic tumour therapy 
ameliorates the prognosis of diverse malignancies. The 
